Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib

Journal of the National Cancer Institute

Volumn 99, Issue 1, 2007, Pages 81-83

  Rini, Brian I ^a   Tamaskar, Ila ^a   Shaheen, Phillip ^a   Salas, Renee ^a   Garcia, Jorge ^a   Wood, Laura ^a   Reddy, Sethu ^b   Dreicer, Robert ^a   Bukowski, Ronald M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; SUNITINIB; THYROID HORMONE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE REDUCTION; FATIGUE; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; KIDNEY METASTASIS; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THYROID FUNCTION TEST; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED DISORDER; KIDNEY TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; HYPOTHYROIDISM; INDOLES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PYRROLES; THYROID FUNCTION TESTS; THYROID HORMONES;

EID: 33846978108     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djk008     Document Type: Article

References (16)

1. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, et al. Discovery of 5-[5-fluoro-2-oxo- 1,2-dihydroindol-(3Z)-ylidenemethyl]-2, 4-dimethyl-lH- pyrrole-3-carboxylic acid (2- diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003;46:1116-9.
2. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003;9:327-37.
3. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24:16-24.
4. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 2006;295:2516-24.
5. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe R, et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-α) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). 2006 American Society of Clinical Oncology Annual Meeting Proceedings Pt I. Vol 24 June 20 Suppl); 2006: LBA3.
6. Demitri GD, van Oosterom AT, Blackstein M, Garrett C, Shah M, Heinrich M, et al. Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of SU11248 in patients (pts) following failure of imatinib for metastatic GIST. 2005 American Society of Clinical Oncology Annual Meeting Proceedings Pt I of II. Vol 23 Qune 1 Suppl); 2005:4000.
7. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Nad Cancer Inst 2000;92:205-16.
8. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol 2000;166:475-80.
9. Viglietto G, Romano A, Manzo G, Chiappetta G, Paoletti I, Califano D, et al. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-l/KDR) byTSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascu- larization. Oncogene 1997;15:2687-98.
10. Wang JF, Milosveski V, Schramek C, Fong GH, Becks GP, Hill DJ. Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function. J Endocrinol 1998;157:5-12.
11. Schoeffski P, Wolter P, Himpe U, Dychter SS, Baum CM, Prenen H, et al. Sunitinib- related thyroid dysfunction: a single-center retrospective and prospective evaluation. J Clin Oncol 2006;24:3092.
12. Desai J, Yassa L, Marqusee E, George S, Frates MC, Chen MH, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-4.
13. Atkins MB, Mier JW, Parkinson DR, Gould JA, Berkman EM, Kaplan MM. Hypothyroidism after treatment with mterleukin-2 and lymphokine-activated killer cells. N Engl J Med 1988;318:1557-63.
14. Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, et al. Autoimmunity resulting from cytokine treatment predicts long-term survival in patients with metastatic renal cell cancer. J Clin Oncol 1999;17:529-33.
15. Weijl NI, Van der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder J, et al. Hypothyroidism during immunotherapy with inter- leukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol 1993;11:1376-83.
16. Krouse RS, Royal RE, Heywood G, Weintraub BD, White DE, Steinberg SM, et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with interleukin-2 alone. J Immunother Emphasis Tumor Immunol 1995;18:272-8.